Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
30 března, 2021 7:46 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 8511 Citation: J Clin Oncol...
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)
30 března, 2021 7:42 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 8511 Citation: J Clin Oncol...
Education Session Reviews Current Management of Early-Stage NSCLC, Offers Glimpse of Future Advances
30 března, 2021 7:37 pmJune 3, 2017 Approximately 15% of all patients with non–small cell lung cancer (NSCLC) present with disease in early...
NOVINKY Z LETOŠNÍHO SETKÁNÍ AMERICAN SOCIETY OF CLINICAL ONCOLOGY
30 března, 2021 7:34 pmNa nejvýznamnější sdělení týkající se pokročilého nemalobuněčného karcinomu plic si museli zájemci počkat až na poslední den v sekci těsně před ukončením celé...
Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer
30 března, 2021 7:32 pmMeeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5502 Citation: J Clin Oncol 35, 2017...
Chemotherapy Added to RT Prolongs FFS in Stage III Endometrial Cancer
30 března, 2021 7:25 pmJune 4, 2017 A combination of chemotherapy and radiotherapy prolonged 5-year failure-free survival (FFS) among patients with high-risk, stage...
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
30 března, 2021 2:25 amMeeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5506 Citation: J Clin Oncol 35, 2017...
Trend in OS Benefit with Cediranib for Ovarian Cancer: ICON6 Results
30 března, 2021 1:57 amJune 3, 2017 Median overall survival (OS) was 7.4 months longer among patients with platinum-sensitive, relapsed ovarian cancer who...
A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma
30 března, 2021 1:24 amMeeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5505 Citation: J Clin Oncol 35, 2017...
No Increase in Recurrence-Free Survival with Combined Regimen for Stage III/IVA Endometrial Cancer
30 března, 2021 1:01 amJune 3, 2017 A combined modality regimen did not increase recurrence-free survival (RFS) in patients with optimally debulked stage...